Arrowhead misses the target in alpha-1 antitrypsin deficiency
The Takeda-partnered project fazirsiran shows an impressive reduction in mutant protein, but questions about fibrosis remain.
Flotations fail to bounce back
2022 saw just 19 initial public offerings of drug developers, the lowest total since 2012.
No Blys for Vera
Atacicept hits in phase 2, but uncompetitive data are seen as good news for its IgAN rivals.
Catalysts ahead for the smaller players
Calliditas heads for confirmatory data in IgA nephropathy, while Viking and 89Bio are set for key readouts in Nash.
Biotech’s key upcoming clinical results
Moderna, Biomarin and Daiichi Sankyo will begin 2023 with important data reveals.
Big pharma’s new year catalysts
In the opening months of 2023 Novo Nordisk needs to defend its position, while Daiichi and Astrazeneca await ADC data.
